Covid-19: the Merck laboratory announces that its antiviral reduces the risk of hospitalization by 50% – LCI

RESEARCH – The American laboratory Merck ensures that its antiviral, currently in phase 3 of clinical trials, reduces the risk of hospitalization by 50% and significantly reduces the risk of death.

While vaccines against Covid-19 will soon celebrate the first anniversary of their marketing, treatments against Sars-Cov-2 are still struggling to see the light of day. This Friday, the American laboratory Merck, however, announced promising results for its antiviral, molnupiravir, to be taken orally, in pill form. According to the company, which is developing this treatment with biotechnology company Ridgeback Biotherapeutics, it significantly reduces the risk of hospitalization and death after contracting the virus.

All the info on

Coronavirus: the pandemic that is shaking the planet

To reach this conclusion, the company observed the number of people hospitalized who received this antiviral during phase 3 clinical trials, and that of the control group, which received a placebo. All the participants (775) were people at risk, suffering from Covid-19 in a way “light” Where “moderate”. According to MSD, one month after the start of the trial, “7.3% of patients who received molnupiravir were hospitalized, compared to 14.1% of patients treated with placebo”.

Marketing authorization soon?

Regarding the deaths, the American laboratory notes that on day 29, “no deaths were reported” among the group treated with the antiviral, against eight deaths in the control group. However, these results were published in an official press release and not in a scientific journal. But the lab finds them “positive”. Thus, the study is “prematurely” interrupted.

Read also

The two companies now plan to file a marketing authorization application with the US health safety agency, the FDA. “With these results, we are convinced that molnupiravir can become an important drug in the global effort to fight the pandemic”, says Robert M. Davies, Chairman of Merck. If authorized, then molnupiravir will become the first such antiviral pill used against Covid-19.

Other laboratories are working on antivirals in tablet form, such as the biotech Atea Pharmaceuticals and the Roche laboratory, which are studying the effectiveness of a comparable treatment, called AT-527. The Pfizer laboratory announced Monday that it has started a large-scale clinical trial for its own anti-Covid pill, to test its ability to preventively reduce the risk of infection in those around a person who has contracted the disease. It will be administered in combination with a “low dose” the medicine ritonavir, used against the AIDS virus.

On the same subject

The most read articles

Bygmalion case: Nicolas Sarkozy condemned, Jean Castex reacts on TF1

The increase in the price of electricity will be limited to 4% in February 2022, announces Jean Castex

Serial killer “Le Grêlé” found dead: the epilogue of a 35-year-old affair

A grant of 10,000 euros to help buy your primary residence

Unemployment insurance: what you need to know about the controversial reform in force today

LCI logo
defends the ambition of information
verified and accessible to all thanks to the income of the
advertising .

To help us maintain this free service you can “change your choice” and accept all cookies.

1 thought on “Covid-19: the Merck laboratory announces that its antiviral reduces the risk of hospitalization by 50% – LCI”

Comments are closed.